Protocols & Dosing•August 25, 2026•8 min read

5-Amino-1MQ Dosage: Oral vs SubQ Milligram Ranges Explained

5-Amino-1MQ dosage explained: how oral vs subcutaneous milligram tables differ in community logs versus preclinical NNMT research. Educational only—not a protocol.

PeptIQ Team

Peptide Research & Education

5-Amino-1MQ Dosage: Oral vs SubQ Milligram Ranges Explained

PeptIQ app

Log your NAD+ protocol in PeptIQ

Turn this NAD+ guide into a living protocol — doses, vials, and history in one place.

Track NAD+Open web app

iOS, Android, and web

Research supplier

NAD+ research materials

NAD+ listings are for laboratory / research use only — not for human consumption.

View NAD+ research listing

Research use only. Partner link. PeptIQ may earn a referral fee. Not medical advice.

Tools for this page

Ask PeptIQ

Two taps on our guided quiz, then keep going in iMessage with sources — not Instagram screenshots.

Start the quiz Or try Peptide X Quiz →

# 5-Amino-1MQ Dosage: Oral vs SubQ Milligram Ranges Explained

> Note: PeptIQ is not a medical provider. 5-Amino-1MQ is a research compound, not a peptide in the clinical-peptide sense. This article is educational only.

The existing 5-Amino-1MQ stack guide covers NNMT inhibition and why people discuss it next to GLP-1 agonists and MOTS-c. Search still wants a dedicated 5 amino 1mq dosage page, including oral vs subQ.

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule NNMT inhibitor in preclinical metabolic work. That is a different evidence class from a weekly incretin trial. Dose tables on forums should be read as community habit, not as a labeled schedule.

Evidence tier

Layer	Strength	Limit
Preclinical NNMT / 5-Amino-1MQ papers	Mechanism hypotheses in animals and cells	No consumer milligram label
Stack blogs and logs	Oral capsule versus reconstituted powder stories	Observational
In-app entries	What people record as mg and route	Not outcomes

Do not invent trial PMIDs for a compound that is still mostly preclinical. If a specific paper is not already in the PeptIQ citation corpus, omit it.

Oral versus subcutaneous in community write-ups

Route people name	Why they name it	Caution
Oral capsules	Convenience, daily habit, "research chem" listings	Absorption and identity are listing-dependent
Subcutaneous reconstituted powder	People copy peptide-vial habits	5-Amino-1MQ is not a typical lyophilized peptide workflow

Educational reconstitution math, if someone is holding a claimed powder, is the same generic formula as other research chemicals sold as cakes:

Concentration (mg/mL) = labeled mg ÷ diluent mL

That math does not make the powder 5-Amino-1MQ, and it does not make subcutaneous use a studied human route.

Research-reference ranges versus forum tables

Community tables often discuss daily milligram-scale oral amounts, sometimes split, sometimes stacked with a GLP-1 log or MOTS-c. Those numbers are not a starting-dose instruction. They are what dosage threads repeat.

PeptIQ users who log 5-Amino-1MQ more often record an oral daily field than an injection field. That is a logging observation.

What this page will not do

Convert a GLP-1 weekly milligram into a 5-Amino-1MQ oral milligram
Treat "visceral fat" marketing as a trial endpoint
Publish a buy or source list

Related reading: the 5-Amino-1MQ stack guide for mechanism, the MOTS-c dosage guide for the mitochondrial neighbor, and NAD+ reconstitution education for the NAD-pool conversation people attach to NNMT.

Frequently Asked Questions

Q: Is there an official 5-Amino-1MQ human dose?

A: No labeled consumer schedule. Preclinical NNMT work and community logs are different evidence tiers. Treat forum milligram tables as observational language, not a protocol.

Q: Oral or subcutaneous?

A: Community write-ups mention both. Oral capsules dominate convenience stories. SubQ habits often copy peptide-vial workflows even though 5-Amino-1MQ is not a typical lyophilized peptide product.

Q: Can I convert a retatrutide weekly dose into a 5-Amino-1MQ oral milligram?

A: No. Different mechanisms, different evidence classes. Do not map GLP-1 weekly milligrams onto NNMT-inhibitor forum tables.

Bottom line

5-Amino-1MQ dosage queries outrun the human literature. Oral versus subcutaneous is a community handling split, not a comparative trial. Figures on forums are not a protocol.